Advancements in laboratory techniques for early cancer detection and monitoring DOI Open Access

Heba Mustafa Shaheen,

Abdulrahman Jaber Harbi,

Abdullah Mohsen Khormi

et al.

International Journal of Community Medicine and Public Health, Journal Year: 2023, Volume and Issue: 11(1), P. 424 - 428

Published: Dec. 19, 2023

In years, there have been advancements in laboratory methods for detecting and monitoring cancer at its earliest stages. These breakthroughs revolutionized the field of care with a focus on treatment strategies. This review explores range laboratory-based approaches, including biopsies, advanced imaging technologies like PET, MRI, CT scans, genomic profiling techniques such as next-generation sequencing novel biomarkers, innovative assay platforms, use artificial intelligence-driven analytics. Liquid biopsies are particularly valuable they provide real-time insights into tumor dynamics responses to by analyzing circulating cells cell-free DNA. Advanced modalities offer enhanced sensitivity resolution detection tumors. Genomic help unravel complexities tumors guide therapies. Novel biomarkers show promise types aiding screening prognosis determination monitoring. Innovative platforms allow analysis improve diagnosis. The integration intelligence (AI) machine learning has instrumental interpreting clinical molecular data alongside traditional techniques. However, despite progress made far challenges related standardization, cost effectiveness, ethical considerations persist. It is crucial integrate these practice fully exploit their potential enhancing care.

Language: Английский

Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer DOI Creative Commons
Arianna Marinello, Marco Tagliamento, Arianna Pagliaro

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 129, P. 102791 - 102791

Published: June 23, 2024

Liquid biopsy is a minimally invasive method for biomarkers detection in body fluids, particularly blood, which offers an elevated and growing number of clinical applications oncology. As result the improvement techniques DNA analysis, above all next-generation sequencing (NGS) assays, circulating tumor (ctDNA) has become most informing tumor-derived material types cancer, including non-small cell lung cancer (NSCLC). Although ctDNA concentration higher patients with advanced tumors, it can be detected even early-stage disease. Therefore, numerous management are emerging, such as screening, identification minimal residual disease (MRD), prediction relapse before radiologic progression. Moreover, high trials ongoing to better define impact evaluation this setting. Aim his review offer comprehensive overview on relevant implementations addressing available data, technical aspects, limitations, future perspectives.

Language: Английский

Citations

9
Liquid Biopsy in gastric cancer: a snapshot of the current state of the art DOI Creative Commons
Jessica Gasparello, Carlotta Ceccon, Valentina Angerilli

et al.

The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: 7, P. 100288 - 100288

Published: Jan. 20, 2025

Language: Английский

Citations

1
Circulating Tumor Cells and DNA in Early Diagnosis and Prognosis of Metastatic Cancer DOI Creative Commons

Marium Jahan,

A. Rubab, Mohsin Ali

et al.

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Metastatic cancer remains a major challenge in oncology, often diagnosed late with limited intervention options. This chapter highlights the role of circulating tumor cells (CTCs) and DNA (ctDNA) as biomarkers for early detection, diagnosis, prognosis. Liquid biopsy, non-invasive method, analyzes blood components like CTCs, which provide insights into heterogeneity metastatic potential, ctDNA, reflects genetic mutations burden. These enable real-time monitoring, aiding understanding progression, treatment response, residual disease, resistance mechanisms. Advances detection methods emphasize their clinical relevance personalized treatment. Integrating CTCs ctDNA oncology could revolutionize management through individualized strategies, enhancing outcomes. The concludes challenges future directions implementing these precision oncology.

Language: Английский

Citations

1
Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography DOI

Ziyu Ma,

Junjie Xu,

Weilin Hou

et al.

Analytical Chemistry, Journal Year: 2024, Volume and Issue: 96(13), P. 5195 - 5204

Published: March 23, 2024

The detection of multiple single nucleotide polymorphisms (SNPs) circulating tumor DNA (ctDNA) is still a great challenge. In this study, we designed enzyme-assisted nucleic acid strand displacement amplification combined with high-performance liquid chromatography (HPLC) for the simultaneous three ctDNA SNPs. First, trace could be hybridized to specially template strand, which initiated process under synergistic action polymerase and restriction endonuclease. Then, targets would replaced G-quadruplex fluorescent probes different tail lengths. Finally, HPLC-fluorescence assay enabled separation quantification signals. Notably, method can simultaneously detect both wild type (WT) mutant (MT) Within linear range 0.1 fM–0.1 nM, limits BRAF V600E-WT, EGFR T790M-WT, KRAS 134A-WT V600E-MT, T790M-MT, 134A-MT were 29, 31, 11 aM 22, 33 aM, respectively. By using method, mutation rates SNPs in blood samples from patients lung or breast cancer obtained simple way, providing convenient highly sensitive analytical early screening monitoring cancer.

Language: Английский

Citations

7
Single-tube, Switched Temperature Amplicon Barcoding (STAB-seq) for Multiplex Detection of Rare Mutations in Circulating Tumor DNA. DOI
Tony E. Godfrey,

Ekaterina Kintsurashvili,

Gordana Rasic

et al.

Journal of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Peripheral blood biomarkers in monitoring treatment response in breast cancer patients DOI Creative Commons
Andres A. Ocampo,

Xiaopeng Sun,

Justin M. Balko

et al.

Expert Review of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Keywords: biomarkersbreast cancercell-free DNAcirculating tumor cellsliquid biopsyperipheral blood mononuclear cellsperipheral bloodtranscriptional profilingtreatment response

Language: Английский

Citations

0
Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use? DOI Open Access
Du-Bois Asante, Domenico Tierno, Gabriele Grassi

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1889 - 1889

Published: Feb. 22, 2025

Globally, ovarian cancer (OC) is the eighth most common malignant tumour in women. Unfortunately, its symptoms-especially at early stages-are vague and non-specific, and, thus, patients are diagnosed advanced stages of disease (stage III IV) when treatment not curative. The currently available approved biomarkers sufficient for effective screening, prognosis, or monitoring OC. Liquid biopsy tests such as circulating DNA (ctDNA) analysis has advantage response to real time providing a comprehensive genotypic profile primary, metastatic, recurrent tumours. Thus, ctDNA can be used complementary test diagnosis We comprehensively review current studies (2019-2024) on OC, critically highlighting recent developments applications management disease.

Language: Английский

Citations

0
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients DOI Open Access
Guillaume Herbreteau, M. Marcq, Chloé Sauzay

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 783 - 783

Published: Feb. 25, 2025

Background/Objectives: Circulating tumor DNA (ctDNA) analysis is a powerful tool for non-invasive monitoring of burden and treatment response. Reliable quantification methods are critical the effective use ctDNA as biomarker. Digital PCR (dPCR) offers high sensitivity quantification, but requires prior knowledge tumor-specific genomic alterations. Next-generation sequencing (NGS) provides more comprehensive approach semi-quantitative, relying on variant allelic fraction (VAF), which can be influenced by non-tumor cell-free DNA. Methods: We developed novel quantitative NGS (qNGS) method absolute nucleotide variants, utilizing unique molecular identifiers (UMIs) standards (QSs), short synthetic sequences modified to include characteristic mutations identification in data. evaluated performance this using plasma samples spiked with mutated pools from cancer patients. further applied our technique four non-small cell lung (NSCLC) patients enrolled ELUCID trial. Results: Our qNGS demonstrated robust linearity correlation dPCR both patient-derived samples. Notably, clinical trial revealed ability simultaneously quantify multiple variants single sample. Significant differences levels were observed between baseline post-treatment collected after three weeks front-line therapy. Conclusions: introduce that enables ctDNA, independent circulating variations. This was first time serial NSCLC patients, demonstrating its monitor making it versatile precision oncology.

Language: Английский

Citations

0
AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis DOI Creative Commons
Esther Ugo Alum

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 13, 2025

Cancer remains a significant health issue, resulting in around 10 million deaths per year, particularly developing nations. Demographic changes, socio-economic variables, and lifestyle choices are responsible for the rise cancer cases. Despite potential to mitigate adverse effects of by early detection implementation prevention methods, several nations have limited screening facilities. In oncology, use artificial intelligence (AI) represents transformative advancement diagnosis, prognosis, treatment. The AI biomarker discovery improves precision medicine uncovering signatures that essential treatment diseases within vast diverse datasets. Deep learning machine diagnostics two examples technologies changing way biomarkers made finding patterns large datasets making new make it possible deliver accurate effective therapies. Existing gaps include data quality, algorithmic transparency, ethical concerns privacy, among others. methodologies with seeks transform improving patient survival rates through enhanced diagnosis targeted therapy. This commentary aims clarify how is identification novel optimal focused treatment, improved clinical outcomes, while also addressing certain obstacles issues related application oncology. Data from reputable scientific databases such as PubMed, Scopus, ScienceDirect were utilized.

Language: Английский

Citations

0
Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation DOI
Sia V. Lindskrog, Trine Strandgaard, Iver Nordentoft

et al.

Nature Reviews Urology, Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Language: Английский

Citations

0